US Medicare Pricing Policy May Shift Global Drug Markets

A recent modeling study published in *The Lancet* warns that Medicare’s new “Most‑Favored‑Nation” (MFN) pricing policy could prompt pharmaceutical companies to raise prices or delay product launches. The MFN rule ties the amount Medicare reimburses for a drug to the price paid in other high‑income countries, aiming to curb U.S. drug costs.

According to the analysis, for roughly 75 % of the medicines examined, the projected savings to Medicare would equal nearly four times the drug’s total annual sales in the reference country used to set its price. This disproportionate benefit could give manufacturers a powerful incentive to alter pricing strategies or postpone U.S. launches in order to maintain higher margins abroad.

The study’s authors caution that while the MFN policy may deliver significant cost reductions for Medicare, it could also distort global pricing dynamics and affect drug availability. Policymakers will need to weigh these potential trade‑offs as the program moves forward.